HeartFlow’s NAVIGATE-PCI Registry: New Data Pathway for AI-Guided Stent Planning and HTFL Investors

HeartFlow, Inc. (HTFL) announced an update on their ongoing clinical study.

The NAVIGATE-PCI Registry: A New Approach to VIew CT-derived Guidance Ahead of Stenting To Plan Efficient PCI aims to track how doctors manage coronary artery disease patients before and after HeartFlow’s PCI Navigator is rolled out. The registry focuses on how this AI-based planning tool affects stent strategy, procedure efficiency, and overall care, which could shape how widely hospitals adopt HeartFlow’s platform.

The main intervention is the HeartFlow PCI Navigator, an AI-powered diagnostic planning tool used around stent placement. It builds a 3D, patient-specific view of the coronary arteries and helps cardiologists decide where and how to place stents with less guesswork and potentially less invasive imaging.

The study is observational, not a randomized drug trial, and follows a cohort of patients treated at centers before and after PCI Navigator becomes available. Doctors keep their normal decision-making, and researchers compare outcomes across three groups to see how access to the tool changes planning and procedure use in real-world practice.

Group 1 includes patients who had CT scans and elective PCI before PCI Navigator was introduced. Groups 2 and 3 cover intraprocedural and preprocedural planning after the tool goes live, letting investors see how quickly and how deeply the software integrates into everyday cath lab workflow.

The registry is planned to run for up to five years, giving a long window to track adoption trends and workflow changes. The record shows initial submission on March 11, 2026, with the latest update on March 16, 2026, signaling the protocol is current and sites are preparing to start enrollment.

For investors, this update reinforces HeartFlow’s push to expand from noninvasive CT-based diagnostics into PCI planning, a larger and stickier software niche. Positive data showing fewer invasive tests, faster procedures, or better planning would support higher utilization, stronger recurring revenue, and could lift sentiment on HTFL compared with imaging and cath lab software peers.

Competitors in cardiac imaging and physiology software, including major device makers and imaging vendors, are also investing in AI-driven planning tools. If NAVIGATE-PCI demonstrates clear workflow or cost advantages, it could strengthen HeartFlow’s position as a preferred partner for hospitals, improving its negotiating leverage and ecosystem value over time.

While there are no outcome results yet, the launch of this registry shows management is serious about building a robust clinical and economic evidence base around PCI Navigator. The study is currently listed as not yet recruiting but recently updated, and further details are available on the ClinicalTrials portal.